Akari Therapeutics Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed on May 21, 2018, by Akari Therapeutics Plc, a foreign private issuer headquartered in London, United Kingdom. The filing serves to disclose a material event regarding the Company's compliance status with The Nasdaq Stock Market LLC.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of regulatory status rather than a financial statement.
Material Changes
On May 17, 2018, the Company received a notice from Nasdaq stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1). The non-compliance is due to the failure to timely file its Annual Report on Form 20-F for the fiscal year ended December 31, 2017.
Outlook, Risks, and Management Commentary
The primary risk identified is the potential loss of listing status on Nasdaq due to the late filing of the 2017 Annual Report. The document incorporates a press release (Exhibit 99.1) detailing this notice. No forward-looking guidance or financial outlook is provided in this specific filing.
Key Facts for Investor Verification
- Verify the current status of the Form 20-F for the year ended December 31, 2017, and whether it has since been filed.
- Confirm if the Company has received a formal hearing or appeal opportunity from Nasdaq regarding the delisting notice.
- Review the attached press release (Exhibit 99.1) for any additional details on the timeline for regaining compliance.
- Check for subsequent filings to determine if the Company has addressed the listing deficiency.